Question : 90-90-90 Targets by 2035

Will the Minister of HEALTH AND FAMILY WELFARE be pleased to state:

(a) whether as per the report of World Health Organisation (WHO) deaths attributable to tuberculosis in India has declined by 12 per cent since last year even though the number of new cases have increased by a five per cent and if so, the details thereof;

(b) whether India accounts for about 32 per cent of deaths due to this disease in the world and if so, the details thereof along with the number of deaths recorded during the last three years and the current year, State/UT and year-wise;

(c) whether the Government has introduced Daily Drug Regimen for the treatment of TB under the Revised National TB Control Programme (RNTCP), if so, the details thereof along with the incidence of TB Cases and mortality as a result thereof during the said period; and

(d) whether Multi Drug Resistant TB (MDR-TB) and HIV associated TB have become major health security threat and if so, the details thereof along with the corrective measures taken by the Government to facilitate the treatment along with the impact of schemes/programmes
implemented to control TB and the details of strategic plan being worked out for elimination of TB from the country; and 69 70

(e) whether it is also true that the Government has committed to achieve the 90-90-90 targets by 2035 and if so, the details thereof?

ANSWER
THE MINISTER OF STATE IN THE MINISTRY OF HEALTH AND
FAMILY WELFARE
(SHRI ASHWINI KUMAR CHOUBEY)
(a): Yes. As per the Global TB Report 2017, in India, the mortality due to TB has decreased from 36 per lakh population in the year 2015 to 32 per lakh population in the year 2016. Also, the estimated new cases of TB in India have reduced from 217 per lakh population in 2015 to 211 per lakh population in 2016.



Under the programme, the notification of new cases has increased from 1423181 in 2015 to 1424771in 2016 due to the increase in notification of cases from private sector, as a result of proactive steps taken by the Government for engaging with the private sector.

(b): Yes. As per the Global TB Report 2017, India accounts for 32 percent of deaths due to TB in the world.
The State wise and Year wise details of number of deaths reported in the program during the last three years and the current year so far, is at Annexure.

(c): Yes. The program has been introduced and scaled up Daily Drug Regimen with Fixed Dose Combination drugs for the treatment of all TB patients across the country since October 2017.

From October 2017, all TB patients in the country are being provided with daily drug regimen anti TB drugs including the patients seeking care in the private sector and who want to avail these benefits.

As per the Global TB Report 2017, the incidence of TB cases in India in the year 2016 was 211 cases per 1 lakh population and mortality was 32 cases per 1 lakh population.

(d) & (e): No. As per the Global TB Report 2017, WHO estimates for HIV TB cases in India, in the year 2016 is 87000 (3% of total TB cases) and estimated MDR/RR TB cases among notified pulmonary TB cases is 84000.

Under Revised National TB Control Programme (RNTCP), the treatment for HIV associated TB cases is available as a “single window delivery service” wherein all HIV/TB co-infected patients get their TB medications free of cost from Anti-retroviral centres across the country. All diagnostic and treatment services for MDR TB are available free of cost under RNTCP.

As per the Global TB Report 2017, the incidence of TB has reduced from 289 per lakh per year in 2000 to 211 per lakh per year in 2016 and mortality has reduced from 56 per lakh per year in 2000 to 32 per lakh per year in 2016.

The National Strategic Plan (NSP) for Tuberculosis (2017-25) has been formulated by the Ministry of Health and Family Welfare.In addition to the existing strategies under RNTCP, the NSP focusses on:

• early diagnosis of all the TB patients, prompt treatment with quality assured drugs and treatment regimens
• suitable patient support systems to promote adherence.
• engaging with the patients seeking care in the private sector.
• prevention strategies including active case finding and
• contact tracing in high risk / vulnerable population
• airborne infection control.